Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity, with IC50s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 51.00 | |
2 mg | In stock | $ 74.00 | |
5 mg | In stock | $ 118.00 | |
10 mg | In stock | $ 198.00 | |
25 mg | In stock | $ 452.00 | |
50 mg | In stock | $ 665.00 | |
100 mg | In stock | $ 947.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 129.00 |
Description | ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity, with IC50s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively. |
Targets&IC50 | C481S-BTK:0.39 nM, WT-BTK:0.85 nM |
In vitro | In vitro treatment of patient CLL cells with ARQ 531 decreases BTK-mediated functions including B-cell receptor (BCR) signaling, viability, migration, CD40 and CD86 expression, and NF-κB gene transcription.?Additionally, ARQ 531 inhibits CLL cell survival and suppresses BCR-mediated activation of C481S BTK and PLCγ2 mutants, which facilitate clinical resistance to ibrutinib[2]. |
In vivo | In vivo, ARQ 531 was found to increase survival over ibrutinib in a murine Eμ-TCL1 engraftment model of CLL and a murine Eμ-MYC/TCL1 engraftment model resembling Richter transformation[2]. |
Molecular Weight | 478.93 |
Formula | C25H23ClN4O4 |
CAS No. | 2095393-15-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (104.40 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ARQ 531 2095393-15-8 Angiogenesis Tyrosine Kinase/Adaptors BTK Btk MK1026 MK 1026 ARQ-531 Inhibitor inhibit ARQ531 Bruton tyrosine kinase MK-1026 inhibitor